MedTrace Logo

Ibudilast for the Treatment of Alcohol Use Disorder

NCT03594435 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2024-11-27

Study results available
· View outcomes & findings →

Summary

This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week medication treatment period and 5 in-person visits over 16 weeks.

Conditions

Interventions

DRUG

Ibudilast

targets neurotrophin signaling and neuroimmune function

DRUG

Placebo oral capsule

matched to active drug, ibudilast

Sponsors & Collaborators

Principal Investigators

  • Lara A. Ray, PhD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2023-04-19
Completion
2023-04-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03594435 on ClinicalTrials.gov